HC Wainwright & Co. Reiterates Buy on Halozyme Therapeutics, Maintains $95 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 92.8%

Neg 0% Neu 92.8% Pos 0%

HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Halozyme Therapeutics (NASDAQ:HALO) with a Buy and maintains $95 price target.